I n n o v a t i n g
t o
t r a n s f o r m
t h e
l i v e s
o f
p a t i e n t s
10
Therapeutic areas
20+
Pipelines
3
Commercialization
/ NDA
/ NDA
Pipeline
Asset
Indication(s)
Pre-clinical
Phase I
Phase II
Phase III
NDA Filing
Approved
Near-Commercial Staged Assets
Solriamfetol
EDS
ADHD & MDD
Cenobamate
Epilepsy
Monarch eTNS 2.0
ADHD
Parkinson’s Platform
Pain Platform
IGS03
Parkinson’s Disease
IGS01
Psychosis in PD
Chronic pain
IGS07
Neuropathic pain conditions
Mood Disorder Platform
IGS05
TRD and other synaptopathies
IGS04
TRD and other synaptopathies
Others
Others
Epilepsy、Schizophrenia、TRD and others
Products
翼弗瑞®，Cenobamate Tablets
A brand-new third-generation anti-seizure medication, it was approved by the National Medical Products Administration (NMPA) of China in 2025, indicated for the treatment of partial-onset seizures in adult patients. Previously, it obtained approvals from the U.S. Food and Drug Administration (FDA) in 2019 and the European Medicines Agency (EMA) in 2021 respectively. To date, it has been launched and approved in 25 countries worldwide.
Boasting superior efficacy and safety profiles, this drug has been granted the high-level/strong recommendation in both the Clinical Practice Guidelines for the Administration of Third-generation Anti-seizure Medications and Sodium Channel Blockers for the treatment of Focal Epilepsy: a Chinese expert Consensus.
Boasting superior efficacy and safety profiles, this drug has been granted the high-level/strong recommendation in both the Clinical Practice Guidelines for the Administration of Third-generation Anti-seizure Medications and Sodium Channel Blockers for the treatment of Focal Epilepsy: a Chinese expert Consensus.
翼朗清®，solriamfetol tablets
A wakefulness-promoting agent with a dual mechanism of action, it was approved by China's National Medical Products Administration (NMPA) in 2025 to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). Previously, the product was approved by the U.S. Food and Drug Administration (FDA) in 2019 and the European Medicines Agency (EMA) in 2020 for the treatment of EDS in adult patients with OSA or narcolepsy.
Demonstrating outstanding efficacy and safety, it has consistently received the highest level and strong recommendations from multiple domestic and international clinical guidelines. These include the Guidelines for the Diagnosis and Treatment of Adult Obstructive Sleep Apnea (2025) and the Guidelines for the Diagnosis and Treatment of Narcolepsy in China (2022 Edition) by the Chinese Medical Association, as well as the Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnia issued by the American Academy of Sleep Medicine (AASM).
Demonstrating outstanding efficacy and safety, it has consistently received the highest level and strong recommendations from multiple domestic and international clinical guidelines. These include the Guidelines for the Diagnosis and Treatment of Adult Obstructive Sleep Apnea (2025) and the Guidelines for the Diagnosis and Treatment of Narcolepsy in China (2022 Edition) by the Chinese Medical Association, as well as the Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnia issued by the American Academy of Sleep Medicine (AASM).
Monarch eTNS 2.0 (Home-use medical device)
*This product has not yet been approved in Mainland China
The first home-use medical device approved by the U.S. Food and Drug Administration (FDA) for the treatment for pediatric ADHD serves as a monotherapy for 7 to 12-year-old patients who are currently not taking prescription ADHD medications. The device's version 2.0 has received FDA approval for market launch in 2024.
R&D
Ignis is committed to leveraging cutting-edge neuroscience research to develop targeted therapies that address the underlying mechanisms of disease progression.
In-house R&D Laboratories
As the scientific engine driving this mission, the company boasts in-house R&D laboratories located in Zhangjiang, Shanghai. The laboratories are staffed by a multidisciplinary team of experts in medicinal chemistry, biology, pharmacology, pharmacokinetics, toxicology, and more. The core management team hails from various innovative multinational pharmaceutical companies globally, bringing with them extensive experience in discovering and advancing multiple drug candidates from concept to clinical stages, including those that have successfully reached the market.
First-in-class/
Best-in-class
Best-in-class
The Ignis R&D Center integrates insights into unmet medical needs with its team's expertise to pioneer First-in-class and Best-in-class medicines. Rooted in human-data-driven hypotheses, the Ignis team harnesses tools such as structural biology, computer- and AI-assisted drug design, alongside in vitro assay and in vivo models for rapid molecule discovery, design, and optimization. Additionally, the team implements biomarker strategies to enhance the efficiency and success rates of early clinical developments.
Strategic Collaborations
The Ignis R&D Center actively cultivates strategic collaborations with both domestic and international pharmaceutical firms and esteemed academic institutions. These partnerships foster groundbreaking innovations in neuroscience, synergizing with Ignis’ internal programs that ultimately enhance the quality of life for patients.
Manufacturing
Ignis GMP manufacturing facilities are located in Suzhou Wu Zhong Biomedical Park, serving as a production site for oral solid formulations of innovative central nervous system (CNS) drugs.
12,300
M2
Manufacturing
Building Spaces
Building Spaces
Adhering to the principles of green, low-carbon, and high-energy efficiency, the GMP facilities have established a comprehensive quality management system. Constructed in accordance with the cGMP standards set by NMPA (National Medical Products Administration), FDA (U.S. Food and Drug Administration), and EMA (European Medicines Agency), it incorporates state-of-the-art automated production equipment with advanced technologies. The facilities are operated by experienced and talented professionals who are dedicated to drug research and development and manufacturing, ensuring the production of safe, efficacious, and cost-effectively managed innovative medicines for patients.
1
billion tablets
Annual Production
Capacity
Capacity
"We anticipate collaborating with partners to unlock the full potential of innovations and jointly forge a blueprint for a vibrant, healthier future."
Address
46F, BM InterContinental Business Center, No.100 Yutong Road, Jing’an District, Shanghai, China
